The Asthma-Mental Health Connection: Expert Clinicians Weigh In
Patients with asthma have demonstrated an elevated risk for depression and anxiety that is potentially twice as high as that in the general population.
Depressive Disorder
DEPRESSIVE DISORDER
Features
Latest News
Low Levels of Vitamin D Associated With Depression in Older Adults
Every 10-ng/mL increase in serum 25-hydroxyvitamin D was associated with a 12% decrease in the risk for depression in older adults.
Ketamine for Depression: Clinical Evidence and Concerns
Ketamine is gaining ground as a promising option for treatment-resistant depression, but not every clinician is buying in. We review clinical evidence and concerns surrounding the drug.
Patients With Alopecia Areata at Increased Risk for Depression and Anxiety
Researchers completed a comprehensive meta-analysis examining existing literature to study the relationship between alopecia areata, anxiety, and depression.
Benzodiazepine Monotherapy Often Used for Depression Contrary to Guidelines
Benzodiazepine monotherapy continues to be used to treat depression despite American Psychiatric Association guidelines, and even in cases of concomitant opioid use.
Online Intervention Improves Depression, Anxiety Symptoms in Young Adults
Participants of a cognitive behavioral health-based online intervention showed reduced symptoms of anxiety and depression and high levels of satisfaction in both a routine healthcare setting and a controlled research study.
Standard Tools Validly Assess Depression, Anxiety in Home-Dwelling Seniors
Researchers investigated the validity of the Norwegian versions of the GDS-5 and HADS-D assessment tools among home-dwelling individuals aged 60 years or older.
Depression Symptoms Greater in Mothers With Prior Eating Disorders
Women with eating disorders experience persistently greater depressive symptoms across the life-course.
Anxiety, Stress-Related Disorders Associated With Genetic Variants
Anxiety and stress-related phenotypes correlated with such traits as depression and obesity and smoking.
Esketamine Nasal Spray Effective for Treatment-Resistant Depression
Adult patients with treatment-resistant depression showed a favorable improvement in symptoms after a course of esketamine twice-weekly for 28 days.
DEA Schedules Postpartum Depression Treatment Zulresso
The Drug Enforcement Administration (DEA) has placed Zulresso (brexanolone; Sage Therapeutics), a treatment for postpartum depression, into Schedule IV of the Controlled Substances Act.
Want to read more?
Please login or register first to view this content.
Next post in Depressive Disorder